Alnylam Clinical Data Supports Amvuttra Efficacy Across ATTR Patient Subgroups

New clinical findings from Alnylam demonstrate that its ATTR amyloidosis treatment, Amvuttra, delivers consistent therapeutic benefits across diverse patient demographics, further supporting its potential expansion into hypertension management.